CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-04 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 902,541 |
| 2023-10-04 | Gibson Christopher Chief Executive Officer | Sale | −59,794 | $7.21 | $431K | 842,747 |
| 2023-10-04 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 468,750 | ||
| 2023-10-03 | Borgeson Blake Director | Sale | −8,885 | $7.29 | $65K | 7,434,075 |
| 2023-10-02 | Dar Zavain Director | Grant or award | +1,920 | 73,964 | ||
| 2023-10-02 | CHAVEZ R. MARTIN Director | Grant or award | +2,619 | 56,177 | ||
| 2023-10-02 | Li Dean Y Director | Grant or award | +1,659 | 1,326,415 | ||
| 2023-09-28 | Larson Tina Marriott President and COO | Exercise or conversion 10b5-1 | +3,000 | $1.06 | $3K | 421,782 |
| 2023-09-28 | Larson Tina Marriott President and COO | Sale 10b5-1 | −3,000 | $7.72 | $23K | 418,782 |
| 2023-09-28 | Larson Tina Marriott President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,000 | 526,000 | ||
| 2023-09-19 | Borgeson Blake Director | Sale | −8,885 | $8.36 | $74K | 7,442,960 |
| 2023-09-15 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +18,000 | $2.22 | $40K | 158,351 |
| 2023-09-15 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −18,000 | $8.66 | $156K | 140,351 |
| 2023-09-15 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −18,000 | 433,469 | ||
| 2023-09-15 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 881,291 | ||
| 2023-09-15 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 871,291 | ||
| 2023-09-15 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,511,496 | ||
| 2023-09-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 913,186 |
| 2023-09-13 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $8.69 | $217K | 888,186 |
| 2023-09-13 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,335,135 |
Page 31 of 41 · 805 trades